Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Rheumatology and Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Clin Immunol. 2023 Nov;256:109804. doi: 10.1016/j.clim.2023.109804. Epub 2023 Oct 12.
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs), which can lead to thrombosis and pregnancy complications. Within the diverse range of aPLs, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have gained significance in clinical practice. The detection of aPS/PT has proven valuable in identifying APS patients and stratifying their risk, especially when combined with other aPL tests like lupus anticoagulant (LA) and anti-β-glycoprotein I (aβGPI). Multivariate analyses have confirmed aPS/PT as an independent risk factor for vascular thrombosis and obstetric complications, with its inclusion in the aPL score and the Global Anti-Phospholipid Syndrome Score (GAPSS) aiding in risk evaluation. However, challenges remain in the laboratory testing of aPS/PT, including the need for assay standardization and its lower sensitivity in certain patient populations. Further research is necessary to validate the clinical utility of aPS/PT antibodies in APS diagnosis, risk stratification, and management.
抗磷脂综合征（APS）是一种自身免疫性疾病，其特征是存在抗磷脂抗体（aPLs），这可能导致血栓形成和妊娠并发症。在各种 aPLs 中，抗磷脂酰丝氨酸/凝血酶原抗体（aPS/PT）在临床实践中具有重要意义。检测 aPS/PT 已被证明有助于识别 APS 患者并对其进行风险分层，尤其是与狼疮抗凝物 (LA) 和抗β-糖蛋白 I (aβGPI) 等其他 aPL 检测方法联合使用时。多变量分析证实 aPS/PT 是血管血栓形成和产科并发症的独立危险因素，其纳入 aPL 评分和全球抗磷脂综合征评分（GAPSS）有助于风险评估。然而，aPS/PT 的实验室检测仍存在挑战，包括需要进行检测标准化，以及在某些患者群体中的敏感性较低。需要进一步研究来验证 aPS/PT 抗体在 APS 诊断、风险分层和管理中的临床实用性。
